Drugs News and Research

RSS

New artificial intelligence tool identifies aging patterns in hematopoietic stem cells

Aging progressively affects the functioning of our body and, among other things, deteriorates the ability of the hematopoietic system- the set of organs and tissues responsible for producing blood cells- to maintain adequate blood cell production.

28 Sep 2026

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

28 Sep 2026

An AI-identified biomarker can look accurate and still fail its biggest test

The review examines how AI combines molecular, imaging, circulating, cellular, and digital data to identify potential disease biomarkers. Its authors argue that independent validation, biological testing, and evidence of better clinical decisions are needed before those candidates enter patient care.

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

UCLA researchers present new radiation advances at ASTRO 2026

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer control while limiting treatment side effects.

25 Sep 2026

AI-based model predicts glioblastoma recurrence to guide targeted treatment

A new AI-based model can predict where glioblastoma is most likely to return after initial surgery, potentially giving doctors a chance to treat it before it becomes visible on MRI.

25 Sep 2026

Toxoplasma remodels host cell surfaces to trigger invasion

At first, cholesterol and glycosylation seemed like two separate leads. As the researchers followed them, however, the pathways converged.

25 Sep 2026

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

New project aims to make cellular therapies more accessible through room temperature storage

The Advanced Research Projects Agency for Health, or ARPA-H, has executed an award of up to $36.5 million in support of a University of California, Davis-led project aiming to make cellular therapies cheaper and more accessible through room temperature storage.

25 Sep 2026

Researchers find how prostate tumors reshape the immune microenvironment

Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment.

25 Sep 2026

Blood proteins may help monitor Alzheimer’s treatment response

Patients with early symptoms of Alzheimer's disease may be prescribed anti-amyloid therapy, which can help clear the sticky clumps of amyloid protein in the brain that characterize Alzheimer's.

25 Sep 2026

Neuromedin U drives immune suppression in aggressive prostate cancer

A new study from The Wistar Institute has found a link between the nervous system and the rapid development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease.

24 Sep 2026

USP15 enzyme emerges as potential target for ovarian cancer treatment

Ovarian cancer is often diagnosed after it has already spread to other parts of the body, at which point the five-year survival rate is under 30 percent.

24 Sep 2026

Study identifies shared pathway driving cardiac fibrosis

Three adenosine receptor subtypes that normally send different signals were found to converge on a common pathway that activates cardiac fibroblasts, the scar-forming cells in the heart.

24 Sep 2026

MIT biologists discover cellular pathway that triggers colon cancer spread

Most colon cancer deaths are caused by the spread of tumor cells beyond the colon, usually to the liver. In a new study, MIT biologists identified a cellular pathway necessary for colorectal cancer metastasis.

24 Sep 2026

Multi-million dollar grants aim to advance hairy cell leukemia research

The Hairy Cell Leukemia Foundation and Blood Cancer United®, formerly The Leukemia & Lymphoma Society, today announced six new research grants as part of their ongoing strategic partnership to better understand what drives hairy cell leukemia and find better therapies on the road to cures for this rare form of blood cancer.

24 Sep 2026

Multiple immunosuppressive therapies increase infection risks for cancer patients

Retrospective analysis of more than 20,000 patient records identifies opportunities for risk-mitigating approaches in certain patient populations.

24 Sep 2026

Scientists uncover molecular mechanism that tunes eye light sensitivity

Weill Cornell Medicine investigators have determined the mechanism by which a molecule within cells can help tune the light sensitivity of the eyes.

24 Sep 2026

Engineered nanoparticles sensitize gliomas to radiotherapy

Gliomas are a major cause of cancer-related deaths in younger adults.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026